摘要
无法区分免疫接种和自然感染是限制布氏杆菌疫苗应用的主要原因。本研究通过基因同源重组技术,用氯霉素抗性基因(Cmr)替代布氏杆菌弱毒S2株的WbkC基因,筛选获得重组布氏杆菌rS2-WbkC株。试验发现,重组菌rS2-WbkC由原先的光滑型转变成粗糙型。rS2-WbkC在TSA培养基上传25代后仍能稳定表达氯霉素抗性蛋白。小鼠动物试验模型表明,rS2-WbkC与S2有相似的保护性,但rS2比S2具有更高的安全性。rS2-WbkC免疫小鼠后,其抗血清可通过平板凝集试验与S2免疫的血清相区分。本研究为布氏杆菌标记疫苗的研制提供了技术平台。
Vaccination has not been used widely because of the interference in the discrimination between infected and vaccinated animals in immune-screening procedures. In the present study, chloramphenicol resistance gene（ Cm′） was cloned into the genomic DNA of brucella suis S2 strain by homologous recombination with knocking out the WbkC gene, and obtained the recombinant rS2-WbkC. Further study confirmed that rS2-WbkC was conversed into rough-phenotype form smooth-phenotype. The recombinant keeps the ability to chloramphenicol resistance after 25 passages in tryptic soy agar （TSA）. Mice tests showed rS2-WbkC offered similar protection to S2 strain, but more safe than S2. Serum collected form rS2-WbkC immunized mice could be easily distinguished from antiserum produced by smooth-phenotype brucella abortus. In view of these result, rS2-WbkC is a promising candidate for vaccine strain.
出处
《微生物学报》
CAS
CSCD
北大核心
2007年第6期978-981,共4页
Acta Microbiologica Sinica
